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Abstract  49 
 50 
Background: 51 
A significant number of melanoma patients develop local or metastic recurrence, and early 52 
detection of these is vital to maximise benefit from new therapies such as inhibitors of BRAF and 53 
MEK, or immune checkpoints. This study explored the use of novel DNA copy number profiles in 54 
circulating cell-free DNA (cfDNA) as a potential biomarker of active disease and survival. 55 
 56 
Patients and Methods:  57 
Melanoma patients were recruited from oncology and dermatology clinics in Sheffield, UK and 58 
cfDNA was isolated from stored blood plasma. Using low-coverage whole genome sequencing, we 59 
created copy-number profiles from cfDNA from 83 melanoma patients, 44 of whom had active 60 
disease. We used scoring algorithms to summarize copy-number aberrations, and investigated 61 
their utility in multivariable logistic and Cox regression analyses. 62 
 63 
Results:  64 
The copy number aberration score (CNAS) was a good discriminator of active disease (odds ratio 65 
3.1, (95% confidence interval 1.5, 6.2; p=0.002), and CNAS above or below the 75th percentile 66 
remained a significant discriminator in multivariable analysis for active disease (p=0.019, with area 67 
under Receiver-Operator Characteristic curve of 0.90). Additionally, mortality was higher in those 68 
with CNAS above the 75th percentile, compared to those with lower scores (HR 3.4, 95%CI 1.5 ± 69 
7.9, p=0.005), adjusting for stage of disease, disease status (active/resected), BRAF status and 70 
cfDNA level.  71 
 72 
Conclusion: 73 
This study demonstrates the potential of a de novo approach utilising copy-number profiling of 74 
cfDNA as a biomarker of active disease and survival in melanoma. Longitudinal analysis of copy-75 
number profiles as an early marker of relapsed disease is warranted. 76 
  77 
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INTRODUCTION 78 
Melanoma is the most aggressive form of skin cancer, and is increasing in incidence throughout 79 
the developed world, with around 15,900 new cases and 2,285 deaths from melanoma in the UK in 80 
2015 [1]. Prognosis is known to correlate with Breslow thickness, the presence of tumour ulceration 81 
and mitotic rate [2]. Patients with thicker melanomas (defined as >2mm with ulceration or >4mm 82 
without ulceration) have >50% chance of relapse [3].  83 
 84 
The cornerstone of treatment for loco-regional disease is surgery. However, a significant number of 85 
patients later develop local or systemic recurrence. Advanced disease is usually fatal. Until 2011, 86 
standard palliative chemotherapy was single agent dacarbazine with a response rate of just 10-87 
15%. Response rates have since improved with the advent of BRAF (B-Raf proto-oncogene, 88 
serine/threonine kinase) inhibitors,  mitogen-activated protein kinase kinase 1 (MEK) inhibitors [4,5] 89 
and immune checkpoint inhibitors that target cytotoxic T-lymphocyte associated protein 4 (CTLA4) 90 
and programmed cell death 1 (PD1) [6,7]. Early detection of metastatic relapse (if possible prior to 91 
onset of clinical symptoms) is vital to maximise the benefit from the new therapies. At the present 92 
time this relies heavily on imaging, but a blood test has the potential to be more sensitive and cost-93 
effective. Although the lactate dehydrogenase (LDH) blood test has been previously used as a 94 
prognostic marker, it is not a clinically useful marker of disease status [2] and better biomarkers of 95 
relapse need to be identified. 96 
 97 
Plasma cfDNA provides an easily accessible source of tumour-derived DNA (ctDNA). Raised levels 98 
of cfDNA are seen in many clinical conditions, when compared with healthy controls [8 -10], and 99 
ctDNA has been detected in the plasma of patients with melanoma [11]. An increase in the overall 100 
amount of tumour-derived DNA in the plasma is frequently correlated with metastatic disease and 101 
relapse, and studies have shown that that tumour specific circulating DNA levels correlate with 102 
tumour burden and relapse following treatment [12-14]. Somatic genomic aberrations characteristic 103 
of the tumour DNA can frequently be seen in the ctDNA [15]. A number of high-profile publications 104 
have demonstrated the potential utility of using genomic profiling techniques to provide biomarkers 105 
of metastatic disease and acquired resistance that can capture tumour evolution and heterogeneity 106 
[16-18]. Copy number abberations (comprising deletions or duplications of large segments of DNA, 107 
ranging in size from a few kilobases to entire chromosomes) are abundant in malignant melanoma 108 
[19]. Such aberrations occur throughout the genome and can be detected by whole-genome highly 109 
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parallel sequencing at low coverage, in contrast to single nucleotide mutations, the detection of 110 
which requires high-coverage targeted sequencing. Copy number analysis in cfDNA therefore has 111 
great potential as a source of biomarkers in melanoma. 112 
 113 
We carried out a feasibility study for patient recruitment, cfDNA sample collection, yield and 114 
stability. To investigate the potential usefulness of low coverage cfDNA sequencing for relapse 115 
detection in melanoma, we investigated whether cfDNA copy-number profiles could be used to 116 
differentiate melanoma patients with active disease from those with recently resected disease.  117 
 118 
MATERIALS AND METHODS  119 
 120 
Patients 121 
Patients were recruited from Dermatology and Oncology outpatient clinics in Sheffield and Barnsley 122 
Hospitals, United Kingdom over an eighteen month period. Eligible patients had a confirmed 123 
diagnosis of cutaneous melanoma of any stage (AJCC melanoma of the skin staging, 7th edition), 124 
and no chemotherapy exposure within the previous four weeks. Patients with either active 125 
unresected disease, or prior resection of their primary tumour or metastatic disease with clear 126 
margins within four weeks of recruitment, were included. Healthy control subjects were co-habiting 127 
partners of study patients or siblings of study patients with no previous cancer diagnosis. All 128 
participants gave informed consent and the study was approved by the local research ethics 129 
committee (REC10/H1003/72). 130 
 131 
Circulating DNA extraction and quantification 132 
Plasma was prepared from blood collected in EDTA vacutainers and processed within 2 hours of 133 
collection, by centrifugation at 800g for 10 minutes at 4°C, followed by ce ntrifugation at 1600g for 134 
10 minutes at 4°C. Aliquotted plasma was stored at -80°C, and centrifuged at 16 00g prior to 135 
extraction of cfDNA.  136 
 137 
Circulating DNA was extracted from 1-2ml plasma from 83 melanoma patients on two occasions; in 138 
2009 using an established in-house phenol-chloroform-based method[20] and in 2016 using the 139 
QIAamp circulating nucleic acid kit (QIAGEN®) according to the manufacturer protocol, but using a 140 
200ul elution volume. cfDNA levels were quantified by SYBR green quantitative real-time PCR (Life 141 
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Technologies), based on an 87bp amplicon in the GAPDH gene. DNA was extracted from patient 142 
tumour and blood lymphocyte samples using Qiagen FFPE and Blood DNA kits respectively, and 143 
was quantified using QUBIT dsDNA BR fluorometric quantitation. Tumour FFPE material was 144 
available for 47 cases, and 21 of these (45%) were previously found to be BRAF V600E mutation 145 
positive by Sanger sequencing (Supplemental Methods). 146 
 147 
Whole-genome library preparation and highly-parallel sequencing 148 
Tumour and lymphocyte DNA samples were sheared to achieve a target size of 200bp. DNA 149 
libraries were prepared using the Ultra II library-prep kit (New England Biolabs®), following the 150 
PDQXIDFWXUHU¶Vprotocol. Libraries were multiplexed in equimolar amounts at 48 samples per flow 151 
cell of the Illumina HiSeq-2500®. Samples of melanoma MDA-MB-435 cell line DNA were included 152 
in each sequencing run to assess inter-run variability. The software CNANORM was used to 153 
generate copy number ratios for cfDNA and tumour DNA for 1 Mb windows across the genome 154 
(see Supplemental Methods).  155 
  156 
Calculation of copy number aberration and extreme copy number aberration scores 157 
Z-scores for each 1Mb window were calculated by standardizing the copy number ratio to the mean 158 
copy-number ratio from a cohort of 20 healthy controls (mean ratio 1.00059, standard deviation 159 
0.0049). These controls were relatives (partners or siblings) of melanoma patients recruited to the 160 
Markers of Relapse in Melanoma study (REC14/YH/1275). A CNAS was then calculated for each 161 
cfDNA sample by summing the square of Z-scores across the genome, as described by Heitzer et 162 
al [21]. In addition, we estimated a score based on high-amplitude aberrations ("eCNAS"), by 163 
summing the squares of the 95-99th percentile of the standardized z-scores, an approach similar to 164 
that used in the plasma genomic abnormality score [22].  165 
 166 
Statistical analyses 167 
Univariable logistic regression analyses comparing active and resected melanoma included log 168 
CNAS, log eCNAS, log cfDNA level (ng/ml plasma), stage at recruitment (coded as binary I/II vs. 169 
III/IV), age at recruitment, gender and BRAF V600E mutation status. Significant variables (p<0.05) 170 
were included in a multivariable logistic regression, and predicted probabilities based on the model 171 
were used to generate Receiver-Operator Characteristic curves. 172 
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Patient deaths were determined from hospital records, up to a last date of follow-up of 16.08.17. 173 
Survival times were plotted using the Kaplan Meier method, and hazard ratios derived in a Cox 174 
regression framework with adjustment for time from diagnosis to recruitment. Tumour-related 175 
factors significant at the p<0.05 level were included in a multivariable survival analysis All analyses 176 
were implemented in Stata (version 12) and statistical tests were two-sided. 177 
 178 
RESULTS  179 
 180 
Characteristics of melanoma patients with active or recently-excised disease 181 
The demographic and clinical characteristics of the study subjects are shown in Supplemental 182 
Table 1. Over an 18 month period, 108 eligible patients were approached and 83 (77%) recruited, 183 
the majority (75%) through oncology clinics. Thirty-nine cases had recently excised disease, with 184 
median (range) time since excision of 25 (10-71) days. Forty-four cases had active unresected 185 
melanoma with 95% of these being stage III or stage IV disease at the time of recruitment 186 
(Supplemental Table 1). In total, 28 patients (34%) had stage I/II disease and 55 (66%) had stage 187 
III/IV disease. Twenty-eight (34%) of the 83 patients remained alive at the data analysis cut-off. 188 
 189 
Circulating cfDNA levels were stable after long-term plasma storage and were higher in 190 
patients with active disease 191 
The yields of cfDNA extracted from stored blood plasma samples at two timepoints 7 years apart 192 
were highly comparable (Spearman's correlation for log cfDNA level=0.75, p<0.0001; 193 
Supplemental Figure 1), with a median drop in yield of 2.8 (interquartile range 0.6-6.2) ng/ml 194 
plasma over that time period. The drop in yield was slightly higher in those with stage III/IV disease 195 
compared to those with stage I/II disease (p=0.02), but there was no differential drop between 196 
active or resected disease (p>0.05). We carried out a pilot analysis to demonstrate that the BRAF 197 
V600E mutation could be detected in the cfDNA, and found that 14 of 76 (18%) cfDNA samples 198 
successfully amplified were mutation positive, including 6 with recently resected disease. 199 
 200 
As expected, melanoma patients (n= 83) had higher levels of cfDNA compared to control subjects 201 
(n= 75) (p=0.004), and patients with active disease (n=44) had higher levels of cfDNA (median 202 
(range) 11.5 (0.9-114.3) ng/ml) compared to those who had previously excised disease (n=39; 203 
median (range) 5.8 (1.4-19.6) ng/ml; p=0.004; Supplemental Figure 2, Supplemental Table 2). The 204 
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cfDNA levels in those with recently excised disease were similar to those in healthy controls (n=75; 205 
median (range) 5.3 (0.7-33.7) ng/ml; p=0.45; Supplemental Figure 2).  206 
 207 
Low coverage copy number analysis of cfDNA  208 
All 83 cfDNA samples were successfully sequenced, with a median of 15.3 million reads per 209 
sample (range 6.6±36.1 million reads).  On average, 89% of reads aligned to the human reference-210 
genome GRCh38, with a range of 0.1-0.9X coverage of the genome (median 0.4X coverage). 211 
Genomic DNA extracted from the melanoma cell line MDA-MB-435 was analysed on 10 212 
sequencing runs, and the eCNAS and CNAS were calculated to quantify the gains and losses 213 
genome-wide (Supplemental Figure 3). The CNAS yielded highly reproducible results (coefficient of 214 
variation (CV)=0.098), although the eCNAS score was more variable (CV=0.60). To estimate assay 215 
sensitivity, 12ng each of serial dilutions of MDA-MB-435 DNA in lymphocyte DNA were analysed. 216 
Copy-number aberrations could be detected as a raised CNAS above baseline at dilutions as low 217 
as 6.25% cell-line DNA (Supplemental Figure 4).  218 
 219 
Figure 1 shows representative examples of CNA plots for cfDNA compared to matched tumour 220 
FFPE DNA. The blood sample for patient 60 was taken 1 year after the date of the tumour FFPE 221 
sample, and, consistent with active disease and an an evolving tumour, some CNA are present in 222 
both sample types, but in addition CNA are lost and gained in the cfDNA sample compared to the 223 
earlier tumour FFPE sample. The blood sample for patient 5 was taken only 28 days after resection 224 
of the primary tumour, and the cfDNA sample shows some remaining CNA despite the recent 225 
resection of the tumour. This observation is consistent with the presence of residual disease, and 226 
this patient's subsequent relapse. The CNAS for all patients are listed in Supplemental Table 2. 227 
 228 
CfDNA CNAS can distinguish active melanoma from recently-excised disease  229 
CNAS for cfDNA  were higher for cases with active disease compared to those with recently-230 
excised disease (p=0.0011). However there was no significant difference in the eCNAS scores 231 
between the two groups (p=0.14; Figure 2). 232 
 233 
Univariable logistic regression analysis comparing patients with active melanoma to those with 234 
resected disease identified log CNAS, log cfDNA level and disease stage as significant predictors 235 
for the presence of active disease (Table 1). To explore the relationship between CNAS and the 236 
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presence of active disease, patients were grouped according to their CNAS quartile. Those in the 237 
highest quartile had a significantly increased risk of active disease (OR (95% CI) 46.7 (5.0, 431.6), 238 
p=0.001) compared to those in the lower three quartiles. A multivariable logistic regression 239 
analysis, adjusting for cfDNA level and stage, and including a binary coding of logCNAS (above 240 
and below the 75th percentile), showed that CNAS was a significant predictor of active disease (OR 241 
(95% CI) 17.4 (1.6, 190.9), p=0.019, area under ROC=0.90, Table 1).  242 
 243 
The cfDNA CNAS is associated with patient survival 244 
Univariable Cox regression analysis identified log CNAS, log cfDNA level, disease stage, BRAF 245 
V600E status and the presence of active disease as significant predictors of overall survival in 246 
melanoma patients (Table 2). Mortality was higher among those with log CNAS above the 75th 247 
percentile, with HR (95% CI) of 7.7 (4.2,14.2); p<0.0001, Figure 3). Median overall survival for 248 
those with CNAS above the 75th percentile was 13.5 months, compared to 73.8 months for those 249 
with scores <75th percentile. This association remained significant after adjusting for the other 250 
variables (HR (95%CI) 3.4, (1.5±7.9, p=0.005) (Table 2).  251 
 252 
DISCUSSION  253 
 254 
This study aimed to use low coverage copy-number analysis in cfDNA  to detect active disease in 255 
melanoma. This assay does not require any prior knowledge about which mutations are present in 256 
the tumour, unlike methods which track tumour-specific mutations. We have successfully 257 
generated copy-number profiles using low-coverage whole-genome sequencing with very low-input 258 
DNA, thus demonstrating the utility of this de novo approach, which could have clinical applicability 259 
in a variety of other cancer sub-types. While we have presented representative examples of CNA 260 
plots in cfDNA compared with matched FFPE tumour DNA in Figure 1, we did find that for some 261 
cases with active disease, the cfDNA CNA plots showed a paucity of copy-number aberrations, 262 
despite the corresponding tumour DNA harbouring multiple aberrations. While some of this may be 263 
explained by the µdilution effect¶ (tumour-derived aberrant DNA occurring in the background of 264 
predominantly wild-type circulating DNA makes smaller aberrations more dificult to detect in 265 
cfDNA), this represents a limitation of this approach. The modest limit of detection (6.25%) of our 266 
low-coverage approach suggests it is unlikely to be sensitive enough to detect the presence of 267 
active disease in very early-stage disease (where the fraction of tumour-derived DNA is generally 268 
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below 1%). However, the promise of this approach in detecting relapsed metastatic disease (which 269 
is often of moderate-high volume in terms of disease burden) should be highlighted. The sensitivity 270 
of this approach can be improved by combining it with targeted point-mutation detection assays, 271 
given the high prevalence of BRAF/NRAS mutations in melanoma. The detection rate of the BRAF 272 
V600E mutation in our cfDNA samples (18%) is much lower than the expected prevalence of 273 
BRAF-mutated melanoma, reflecting the limited sensitivity of the technique used (Sanger 274 
sequencing). The use of more sensitive techniques, such as droplet digital PCR, can significantly 275 
increase the detection rate.  276 
 277 
We demonstrated that cfDNA is relatively stable in plasma that is appropriately processed and 278 
stored at -80°C, for up to 7 years, with a low median decrease in yield over that ti me period. We 279 
have previously shown that the phenol-chloroform based extraction method gave higher cfDNA 280 
yields compared to kit-based extraction, (although kit-based approaches are more amenable to 281 
high-throughput) [20].  It is likely that the different extraction methods used on the two occasions 282 
could also be contributing to the difference in yields, suggesting that the median drop of 2.8 ng/ml 283 
could be an over-estimate of the effects of storage time. As others have shown [11-13,23], we 284 
found higher levels of cfDNA in melanoma patients, in particular in those with active disease, 285 
compared to controls. It is well established that cfDNA levels can be elevated in other pathological 286 
processes, other than cancer, and following recent surgery, therefore cfDNA level analysis alone is 287 
not a sufficient indicator of the presence of active melanoma. In our cohort, the median duration 288 
from surgery to sampling was 25 days, so, given the short half-life of cfDNA, any temporary rise in 289 
cfDNA levels due to surgery would have recovered by the time of blood-sampling.  290 
 291 
Comparison of the CNAS and eCNAS methods of scoring demonstrated the CNAS to be more 292 
reproducible. The CNAS is a genome-wide score (Heitzer et al [21]) which captures the entire 293 
spectrum of copy-number aberrations regardless of amplitude or length of aberration. In contrast, 294 
the eCNAS score (similar to the PGA score [22,24]) focuses on the 95-99th percentile of copy-295 
number ratios, ignoring the potentially significant contribution made by smaller aberrations, which 296 
may be quite numerous, and it may also exclude some large aberrations.  297 
 298 
The representative cfDNA CNA plots in Figure 1 illustrate that there may be potential to use this 299 
approach to track disease evolution and progression.  However the CNA plots for some cases with 300 
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active disease showed few copy-number aberrations compared to the corresponding primary 301 
tumour DNA. This can arise due to reduction in tumour burden following treatment, and the dilution 302 
of the circulating tumour DNA in the plasma, making detection of CNA more challenging. Despite 303 
this issue, the CNAS for all cases in the present study were above the limit of detection shown in 304 
Supplemental Figure 4, allowing meaningful interpretation of the results.  305 
 306 
Our results showed that the CNAS for cases with active disease were significantly higher than 307 
those with resected disease (p=0.0011). We note however that there is a wide variation in the 308 
CNAS, with some overlap between the scores for active and resected cases. It is possible that the 309 
presence of microscopic residual disease in some patients with resected disease may be 310 
contributing to higher scores in those patients, as suggested by the CNA profile for patient 5 shown 311 
in Figure 1.   312 
 313 
We have also established a multivariable model (based on the CNAS, cfDNA level and disease 314 
stage) which is a good discriminator of active disease, with area under ROC of 0.90. There have 315 
been a number of recent publications which have utilised cfDNA to differentiate melanoma cases 316 
from controls [9] or to assess treatment response in melanoma [25,26]. These studies utilised 317 
either cfDNA levels, mutation analysis (predominantly BRAF) or cfDNA integrity indices (or a 318 
combination of these approaches) in their analyses. We further demonstrated, using a multivariable 319 
Cox regression analysis correcting for other factors known to affect survival, that high CNAS scores 320 
(>75th percentile) were associated with significantly poorer survival. Although our study was not 321 
powered to determine differences by disease stage,, these results are comparable to those of 322 
others [27, 28] who observed that cfDNA predicts relapse and survival in stage II/III melanoma 323 
patients. It would be of value to explore the effects of stage in a larger cohort. 324 
 325 
The study has some limitations. The modest limit of detection (6.25%) suggests that the CNAS is 326 
unlikely to be sensitive enough to detect very early-stage disease (where the fraction of tumour-327 
derived DNA is generally below 1%). In order to improve sensitivity, the CNA approach could be 328 
combined with other genomic markers such as mutation burden in cfDNA. The low detection rate of 329 
the BRAF V600E mutation in our cfDNA (18% compared to 45% in tumour material) reflects the 330 
limited sensitivity of the technique used for this pilot (Sanger sequencing). A further limitation of this 331 
study is the relatively small sample size of the study cohort. While the study had over 90% power to 332 
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detect the observed difference in mean log CNAS between active and resected disease, a larger 333 
replication cohort is required to validate the results and fully assess the performance of the CNAS 334 
controlling for other relevant factors including disease stage and treatment.  335 
 336 
To our knowledge, this is the first application of a cfDNA copy-number approach to predict active 337 
disease and survival in melanoma . Furthermore, our observed associations of CNAS with these 338 
traits suggest that longitudinal analysis of copy-number profiles in melanoma patients is warranted. 339 
The CNAS may act as an early marker of relapsed disease, that could be applied in both research 340 
and clinical settings.  341 
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 421 
Table 1: Logistic regression analysis 
Univariable analysis    
 
OR p-value 95% CI AUC 
log CNAS 3.1 0.002 1.5 - 6.2 0.71 
log eCNAS 3.1 0.099 0.8 - 12.2 0.59 
log cfDNA level 4.2 <0.0001 1.9 - 9.2 0.75 
cfDNA categorya 12.8 0.001 2.7  -  60.0 0.68 
Stage 42 <0.0001 8.8  -  201.3 0.81 
Age 1.0 0.79 0.96  -  1.02 0.53 
Gender 1.2 0.69 0.5  -  2.9 0.52 
BRAF status 1.3 0.59 0.5  -  3.2 0.53 
Multivariable analysis 
 OR p-value 95% CI - 
CNAS categoryb 17.4 0.019 1.6  -  190.90 - 
cfDNA categorya 2.7 0.26 0.5  -  15.1 - 
Stage 24.6 <0.0001 4.4  -  136.9 - 
a
  log cfDNA level above and below the 75th percentile, b log CNAS above and below the 75th percentile 
 
  422 
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Table 2: Cox regression analysis 423 
 424 
 HR p-value 95% CI 
Univariable Cox regression 
log CNAS 2.1 <0.0001 1.6  -  2.7 
log eCNAS 2.1 0.12 0.8  -  5.4 
log cfDNA level 5.5 <0.0001  3.4  -  8.9 
Stage 9.4 <0.0001 4.2  -  21.0 
BRAF status 2.6 0.001  1.4  -  4.5 
Gender 0.7 0.23 0.4  -  1.3 
Active/Resected 9.3 <0.0001 4.9  -  17.3 
Multivariable Cox regression 
CNAS categorya 3.4 0.005 1.5 - 7.9 
cfDNA categoryb 2.3 0.032 1.1 - 4.8 
Stage 3.2 0.016 1.2 - 8.2 
BRAF status 3.2 <0.0001 1.7 - 6.1 
Active/Resected 4.7 <0.0001 2.1 - 10.6 
a
  log CNAS above and below the 75th percentile, b log cfDNA level above and below the 75th percentile 425 
  426 
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Figure 1: Copy-number aberration plot derived from cfDNA extracted from a patient with 427 
active melanoma reflects some aberrations seen in the original tumour biopsy specimen. 428 
Examples of copy-number aberration plots for cfDNA compared to matched tumour FFPE DNA, in 429 
a case with active disease (case 60; top figure) and resected disease (case 5; bottom figure).  430 
 431 
Figure 2: The copy-number aberration scores (CNAS) for cfDNA  were higher for cases with 432 
active disease compared to those with recently-excised disease; while the eCNAS showed 433 
no significant difference between the two groups.  434 
Box and whisker plot of the log scores (log eCNAS on the right, log CNAS on the left) in cases with 435 
active melanoma compared to those with recently-excised disease.  436 
 437 
Figure 3: Mortality was higher in patients with log CNAS above the 75th percentile 438 
Kaplan-Meier survival graph comparing survival for patients with log CNAS above (red) and below 439 
(blue) the 75th percentile. Inset shows the numbers of patients at risk at each time point. 440 
